Vertex Pharmaceuticals Just Found Its Newest Blockbuster Drug. A $41 Billion Market Awaits
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...
Vertex Pharmaceuticals (VRTX) Gets a Buy from Evercore ISI
Evercore ISI analyst Liisa Bayko maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
bovnews7h
Vertex Pharmaceuticals Incorporated (VRTX) Stock Dilemma: A Drop That Has Everyone Talking—What’s the Real Story?
On Wednesday, Vertex Pharmaceuticals Incorporated (VRTX) stock saw a decline, ending the day at $470.05 which represents a decrease of $-4.86 or -1.02% from the prior close of $474.91. The stock ...
Zacks.com on MSN2d
Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know
Vertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at ...
stocknews23h
3 Pharma Stocks to Watch as Gene Therapy Gains Momentum
The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...
Vertex Pharmaceuticals: A Long-Term Growth Monster
Vertex Pharmaceuticals dominates the cystic fibrosis market with a promising pipeline and strategic M&A activity. Read why I ...
Vertex Pharmaceuticals’ Promising Developments and Strategic Market Positioning Reinforce Buy Rating
Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst ...
Barchart on MSN6d
What You Need to Know Ahead of Vertex Pharmaceuticals' Earnings Release
Boston, Massachusetts-based Vertex Pharmaceuticals Incorporated (VRTX) develops and commercializes therapies for treating ...
Business Wire6d
Vertex to Present Phase 3 Data Highlighting Suzetrigine’s Potential as a First-in-Class, Highly Selective Pain Signal Inhibitor at the American Society of Anesthesiologists ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the company will present its pivotal Phase 3 data on ...
BioSpace3d
Vertex Unveils Full Phase III Data for Non-Opioid Pain Candidate, Touts Safety Profile
BMO Capital Markets analyst Evan Seigerman in a note to investors said the late-stage data for Vertex’s experimental ...
BioSpace8h
Massachusetts Tax Incentives for Moderna, Vertex and More Creating 1,155 Jobs
Nineteen companies are receiving $21.4 million total in tax incentive awards to create 1,155 new life sciences jobs in ...
Impacts2d
The Role of Vertex Pharmaceuticals in Boston’s Biotech Boom
Boston has become world-famous for its booming biotech industry. Over the past 20 years, the city has been buzzing with ...